Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia

References

• Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with Chronic Myeloid Leukemia approaches the life expectancy of the general population. J clin oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Apperley J, Lomaia E, et al. OPTIC primary analysis: a dose-optimization study of 3 starting doses of ponatinib (PON). J clin oncol. 2021;39(15_suppl):7000.
   Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of european leukemiaNet. J clin oncol. 2009;27(35):6041–6051.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567–4576.
   PubMed Web of Science ®Google Scholar
• Garcia-Gutierrez JV, Maestro B, Casado LF, et al. Outcomes of Chronic Myeloid Leukemia (CML) patients who stopped second generation tyrosine kinase inhibitors (2GTKIs) As second line treatment. Results of the CML Spanish National Registry (RELMC). Blood. 2012;120(21):3764.
   PubMedGoogle Scholar
• Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361–4368.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010;24(7):1299–1301.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Gambacorti-Passerini C, Abboud C, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34(8):2125–2137.
   PubMed Web of Science ®Google Scholar
• Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116(25):5497–5500.
   PubMed Web of Science ®Google Scholar
• Lipton JH, Bryden P, Sidhu MK, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39(1):58–64.
   PubMed Web of Science ®Google Scholar
• Hughes T. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009;4(1):3–10.
   PubMed Web of Science ®Google Scholar
• Zafar U, Yusuf M, Chakraborty R, et al. The “Gatekeeper” Mutation T315I in BCR/ABL confers additional oncogenic activities to Philadelphia chromosome positive leukemia. Blood. 2019;134(Supplement_1):5196.
   Google Scholar
• Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790–5797.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a Pan-BCR-ABL inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412.
   PubMed Web of Science ®Google Scholar
• Tan FH, Putoczki TL, Stylli SS, et al. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther. 2019;12:635–645.
   PubMed Web of Science ®Google Scholar
• Huang W-S, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I gatekeeper mutant. J Med Chem. 2010;53(12):4701–4719.
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, Bixby D, et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory Chronic Myelogenous Leukemia (CML) and Other hematologic malignancies: emerging safety and clinical response findings. Blood. 2010;116(21):210.
   PubMedGoogle Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood. 2012;120(21):163.
   Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias. N Engl J Med. 2012;367(22):2075–2088.
   PubMed Web of Science ®Google Scholar
• Rossi AR, Breccia M, Castagnetti F, et al. Outcome of patients with CML treated with dasatinib or nilotinib after failure of second prior TKIs. Blood. 2010;116(21):2294.
   Google Scholar
• Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009;114(26):5271–5278.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–123.
   PubMed Web of Science ®Google Scholar
• Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncologica. 2009;48(1):9–17.
   PubMed Web of Science ®Google Scholar
• Emir H, Albrecht-Schgoer K, Huber K, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy In CML. Blood. 2013;122(21):257.
   Google Scholar
• Loren CP, Aslan JE, Rigg RA, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015;135(1):155–160.
   PubMed Web of Science ®Google Scholar
• Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.
   PubMed Web of Science ®Google Scholar
• Takeda US FDA approves supplemental new drug application for Takeda’s ICLUSIG® (ponatinib) for adult patients with resistant or intolerant chronic-phase CML. 2020. [cited 2021 Dec 31]. Available from: https://www.businesswire.com/news/home/20201218005716/en/U.S.-FDA-Approves-Supplemental-New-Drug-Application-for-Takedas-ICLUSIG®-ponatinib-for-Adult-Patients-with-Resistant-or-Intolerant-Chronic-Phase-CML.
   Google Scholar
• Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042–2050.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J clin oncol. 2015;33(35):4210–4218.
   PubMed Web of Science ®Google Scholar
• Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med. 2013;368(11):1055–1056.
   PubMedGoogle Scholar
• Hsu S, Ton V-K, Dominique Ashen M, et al. A Clinician’s Guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins ciccarone center for the prevention of heart disease and american college of cardiology cardiosource approach to the million hearts initiative. Clin Cardiol. 2013;36(7):383–393.
   PubMed Web of Science ®Google Scholar
• Montazeri K, Unitt C, Foody JM, et al. ABCDE steps to prevent heart disease in breast cancer survivors. Circulation. 2014;130(18). DOI:https://doi.org/10.1161/CIRCULATIONAHA.114.008820.
   Google Scholar
• Speck B, Bortin M, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;323(8378):665–668.
   Google Scholar
• Hu B, Lin X, Lee HC, et al. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020;61(12):2811–2820.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Basak GW, Kim D-W, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123(15):2875–2880.
   PubMed Web of Science ®Google Scholar
• Heiblig M, Rea D, Chrétien M-L, et al. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Exp Hematol. 2018;67:41–48.
   PubMed Web of Science ®Google Scholar
• Breccia M, Abruzzese E, Castagnetti F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018;97(9):1577–1580.
   PubMed Web of Science ®Google Scholar
• Shacham-Abulafia A, Raanani P, Lavie D, et al. Real-life experience with ponatinib in chronic myeloid leukemia: a multicenter observational study. Clin Lymphoma Myeloma Leukemia. 2018;18(7):e295–e301.
   PubMedGoogle Scholar
• Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, et al. Discovery of Asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120–8135.
   PubMed Web of Science ®Google Scholar
• Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature. 2017;543(7647):733–737.
   PubMed Web of Science ®Google Scholar
• Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–2041.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Minami Y, Rea D, et al. Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 prior tyrosine kinase inhibitors: update after 48 weeks. Blood. 2021;138(Supplement 1):310.
   Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403–3412.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–2326.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Yang D, Hou Y, et al. An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia. Blood. 2019;134(Supplement_1):493.
   PubMedGoogle Scholar
• Malik S, Hassan S, Eşkazan AE. Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2021;14(11):975–978.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saikia T, Kim D-W, et al. Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Blood. 2020;136(Supplement 1):51–52.
   Google Scholar
• Mian AA, Rafiei A, Haberbosch I, et al. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia. 2014;29(5):1104–1114.
   PubMedGoogle Scholar
• Turkina AG, Vinogradova O, Lomaia E, et al. Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. Blood. 2018;132(Supplement 1):790.
   Google Scholar
• Cortes J, Quintas-Cardama A, Jabbour E, et al. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: is Complete Cytogenetic Response the Only Desirable Endpoint? Clin Lymphoma Myeloma Leukemia. 2011;11(5):421–426.
   PubMedGoogle Scholar
• Lomaia E, Zaritskey A, Shuvaev V, et al. Efficacy of tyrosine kinase inhibitors in third line therapy in chronic phase Chronic Myeloid Leukemia. Blood. 2015;126(23):4051.
   Google Scholar
• Ribeiro BF, Miranda EC, Albuquerque DM, et al. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience. Clinics. 2015;70(8):550–555.
   PubMed Web of Science ®Google Scholar
• Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112(3):516–518.
   PubMed Web of Science ®Google Scholar